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Cytosolic DNA can elicit beneficial as well as undesirable
immune responses. For example, viral or microbial DNA trig-
gers cell-intrinsic immune responses to defend against infec-
tions, whereas aberrant cytosolic accumulation of self-DNA
results in pathological conditions, such as autoimmunity. Given
the importance of these DNA-provoked responses, a better
understanding of their molecular mechanisms is needed. Cyto-
solic DNA engages stimulator of interferon genes (STING) to
activate TANK-binding kinase 1 (TBK1), which subsequently
phosphorylates the transcription factor interferon regulatory
factor 3 (IRF3) to promote interferon expression. Recent studies
have reported that additional transcription factors, including
nuclear factor B (NF-B) and signal transducer and activator
of transcription 6 (STAT6), are also activated by cytosolic DNA,
suggesting that cytosolic DNA-induced gene expression is
orchestrated by multiple factors. Here we show that cytosolic
DNA activates STAT3, anothermember of the STAT family, via
an autocrine mechanism involving interferon  (IFN) and
IL-6. Additionally, we observed a novel cytosolic DNA-induced
phosphorylation at serine 754 in the transactivation domain of
STAT3.UponcytosolicDNAstimulation,Ser754 isdirectlyphos-
phorylated by TBK1 in a STING-dependentmanner.Moreover,
Ser754 phosphorylation inhibits cytosolic DNA-induced STAT3
transcriptional activity and selectively reduces STAT3 target
genes that are up-regulated in response to cytosolicDNA.Taken
together, our results suggest that cytosolic DNA-induced
STAT3activationvia IFN and IL-6 is restrainedbySer754 phos-
phorylation of STAT3. Our findings reveal a new signaling axis
downstream of the cytosolic DNA pathway and suggest poten-
tial interactions between innate immune responses and STAT3-
driven oncogenic pathways.
Double-stranded DNA (dsDNA) in the cytosol is a danger-
associated molecular pattern that triggers inflammation and
immune responses. Cytosolic DNA can be derived from viral
or intracellular microbial infections, undigested phagocytosed
materials, and activated self-retroelements (1). The presence of
cytosolic DNA is detected by several cellular sensors, which
in turn initiate signaling cascades to induce inflammatory
response and type I interferon production (2). Despite the
redundancy between these cytosolicDNAsensors, cyclicGMP-
AMP synthase (cGAS)3 is the predominant sensor relaying the
presence of cytosolic DNA to downstream signaling cascades
(3). Upon binding to dsDNA, cGASproduces cyclic 2-3GMP-
AMP (cGAMP), which serves as a secondmessenger to activate
the endoplasmic reticulum adaptor protein stimulator of inter-
feron genes (STING) (3–6). Activation of STING by cGAMP
leads to STING oligomerization, followed by recruitment and
activation of TANK-binding kinase 1 (TBK1) (7, 8). Subse-
quently, TBK1 phosphorylates interferon regulatory factor 3
(IRF3) to promote expression of interferons (IFNs), thereby ini-
tiating immune responses to establish an antiviral state (7, 9,
10). In addition to IRFs, other transcription factors, including
nuclear factor B (NF-B) and signal transducer and activator
of transcription 6 (STAT6), are also activated by STING and
TBK1 downstream of cytosolic DNA (11–14).
The transcription factor STAT3 is activated by tyrosine 705
phosphorylation downstream of a variety of cytokines, such as
epidermal growth factor (EGF) and IL-6 (15). Phosphorylation
at tyrosine 705 leads to nuclear accumulation of STAT3
homodimers and expression of target genes containing a -ac-
tivated site (GAS) in their promoters (16). STAT3 drives the
expression of prosurvival and inflammatory genes, and sus-
tained activation of STAT3 has been shown to promote prolif-
eration, enhance survival of neoplastic cells, and facilitate
inflammation-driven tumorigenesis (17–19). In addition to its
role in promoting tumorigenesis, STAT3 also represses the
anti-tumor activity of hematopoietic cells, making it a key can-
didate for targeted cancer therapy and immunotherapy (20, 21).
STAT1, another STAT family member, predominantly func-
tions downstream of interferons. STAT1 homodimers induced
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by IFN recognize almost identical GAS sites as STAT3 dimers
do in vitro, but STAT1 and STAT3 have different, albeit over-
lapping, target genes in vivo (22). On the other hand, type I
IFNs, including IFN and IFN, induce the formation of not
only the STAT1 homodimer but also the interferon-stimulated
gene factor 3 (ISGF3) complex comprising STAT1, STAT2, and
IRF9. The ISGF3 complex promotes the expression of genes
containing an IFN-stimulated response element (ISRE) in their
promoters (23). Reciprocal antagonizing effects between
STAT1 and STAT3 can be observed in certain scenarios (24).
For example, STAT3 inhibits STAT1-dependent induction of
ISRE genes in response to type I IFN stimulation presumably
through STAT1-STAT3 heterodimerization (25).
Whereas dimerization and activity of STAT proteins are
controlled by tyrosine phosphorylation, recent studies have
demonstrated that the function of STATs can also be modu-
lated by TBK1 and the closely related kinase IB kinase 
(IKK). Phosphorylation of STAT1 at Ser708 by IKK disrupts
STAT1 homodimerization and favors ISGF3 formation,
thereby shifting the type I IFN-induced gene expression profile
from GAS-driven genes to ISRE-driven genes (26). Cytosolic
nucleic acids and viral infections engage the STING-TBK1
pathway, leading to TBK1-mediated phosphorylation of
STAT6 at Ser407 and STAT6 activation (14). Interestingly,
functional loss of cGAS or STING has been observed in colo-
rectal cancer and melanoma and correlates with disease pro-
gression and elevated STAT3 activation (27–29), suggesting a
role of STING in restricting STAT3 activity and tumor progres-
sion. Thus, we sought to determine whether activity of STAT3
can be regulated by the STING-TBK1 pathway downstream of
cytosolic DNA. Here we show that STAT3 is activated by cyto-
solic DNA through an autocrine mechanism involving IFN
and IL-6. At the same time, cytosolic DNA activates TBK1 in a
cGAS- and STING-dependent manner to directly phosphory-
late STAT3 at serine 754 in the transactivation domain (TAD).
This TBK1-mediated phosphorylation at Ser754 is inhibitory
and restrains cytosolic DNA, IL-6, and IFN-induced activa-
tion of STAT3. Our finding provides a possible explanation for
the role of STING in limiting STAT3 activation and further
emphasizes the complex signaling cascades and gene expres-
sion initiated by cytosolic DNA.
Results
TBK1 Directly Phosphorylates STAT3 at Serine 754—Previ-
ous studies demonstrated that TBK1 and IKK, respectively,
regulate the functionof STAT6andSTAT1bydirect phosphor-
ylation (14, 26). To determine whether TBK1 and IKK also
phosphorylate other STATs, we examined the sequences of
STATs against the optimal substrate motif for TBK1 and IKK
(30, 31) and identified serine 754 in the TAD of STAT3 as a
potential TBK1/IKK phosphorylation site (Fig. 1A). To test
whether STAT3 is a substrate of TBK1 or IKK, IKK and
STAT3 were overexpressed in HEK293T cells, and immuno-
precipitated STAT3 was blotted with an IKK family phospho-
substrate motif antibody (see “Experimental Procedures”).
Overexpression of wild-type IKK strongly induced phosphor-
ylation of STAT3 at Tyr705 as well as a site recognized by the
IKK phosphosubstrate motif antibody (Fig. 1B). We then gen-
erated an antibody specific for phospho-Ser754-STAT3 and
repeated the experiment with TBK1. Similarly, overexpression
of wild-type, but not kinase-dead, TBK1 induced STAT3 phos-
phorylation at multiple sites, and S754A mutation of STAT3
abolished the signal of Ser(P)754-STAT3-specific antibody (Fig.
1C), suggesting thatTBK1kinase activity is critical for the phos-
phorylation of STAT3 at Ser754. Overexpression of TBK1 and
IKK in HEK293T may lead to activation of other kinases,
which in turn phosphorylate STAT3. To determine whether
TBK1 is capable of phosphorylating STAT3 directly, we per-
formed an in vitro kinase assay with purified TBK1 and recom-
binant GST-STAT3 from bacteria. Autoradiography showed
that incubationwithwild-type but not kinase-deadTBK1 led to
strong phosphorylation on wild-type STAT3 and that S754A
mutation of STAT3 abolished the phosphorylation (Fig. 1D).
This TBK1-mediated phosphorylation on STAT3 was also rec-
ognized by the Ser(P)754-STAT3-specific antibody (Fig. 1D).
These data show that TBK1 is capable of directly phosphorylat-
ing STAT3 at Ser(P)754.
STAT3 Is Phosphorylated at Ser754 in Response to Cytosolic
dsDNA—TBK1 is activated downstream of Toll-like receptors
(TLRs) and several other TLR-independent pathways (32). To
determine whether Ser754 phosphorylation of STAT3 occurs
under these conditions, we asked whether these TBK1-activat-
ing agonists promote STAT3 phosphorylation at Ser754. L929
cells were treated with lipopolysaccharide (LPS) or transfected
with poly(I:C), poly(dA:dT), or a 70-bp-long double-stranded
DNA (VACV70mer) (33) to engage TLR4, MDA5/RIG-I, or
the cytosolic DNA pathway, respectively. Transfection with
poly(I:C) or DNA resulted in varying degrees of TBK1, IRF3,
and STAT1 activation, but only transfection with dsDNA,
including poly(dA:dT) and VACV70mer, led to strong phos-
phorylation of STAT3 at Ser754 (Fig. 2A). Induction of STAT3
Ser754 phosphorylation correlated with robust TBK1 activation
(as marked by Ser172 phosphorylation) and phosphorylation of
IRF3, a major substrate of TBK1 (Fig. 2A). STAT3 was also
activated by cytosolic dsDNA transfection, asmarked by Tyr705
phosphorylation, which was accompanied by a modest induc-
tion of Ser727 phosphorylation (Fig. 2A). This demonstrates
that cytosolic dsDNA leads to TBK1 activation, STAT3 activa-
tion, and Ser754 phosphorylation of STAT3. To determine
whether similar responses can be observed in human cell lines,
we tested the human monocytic cell line THP-1 with these
stimuli as well as flagellin, which signals through TLR5. Simi-
larly, cytosolic DNA, especially poly(dA:dT), induced the most
robust Ser754 and Tyr705 phosphorylation of STAT3. This was
accompanied by slight STAT3 Ser727 phosphorylation and
robust activation of STAT1 (Fig. 2B). Poly(dA:dT) transfection
induced association of STAT3 with TBK1 and IKK, whereas
VACV70mer induced association of STAT3with TBK1 but not
IKK (Fig. 2B). These stimuli also induced various degrees of
IKK/IKK activation and p65 phosphorylation, indicative of
NF-B activation (Fig. 2B). Finally, a time course experiment
revealed that association between TBK1 and STAT3 was
induced as early as 1.5 h after dsDNA transfection, coinciding
with the timingofSer754phosphorylation,whereasTyr705phos-
phorylation of STAT3 was detected at a later time point (Fig.
2C). Taken together, these data show that among different
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TBK1 activators, cytosolic DNA induces the most robust
STAT3 activation and phosphorylation at Ser754.
TBK1 Is Required for Cytosolic DNA-induced STAT3 Phos-
phorylation at Ser754—Given that cytosolic DNA induces
robust TBK1 activation, STAT3 phosphorylation, and associa-
tion between TBK1 and STAT3, we asked whether TBK1 is
required for cytosolic DNA-induced Ser754 phosphorylation of
STAT3. We found that STAT3 Ser754 phosphorylation and
IRF3 phosphorylation were abrogated with genetic ablation of
TBK1 or siRNA-mediated TBK1 knockdown (Fig. 3, A and B).
On the other hand, IKK knockdown had negligible effects on
STAT3 Ser754 or IRF3 phosphorylation (Fig. 3C), indicating
that TBK1 but not IKK is required for cytosolic DNA-induced
STAT3 phosphorylation. It has been shown that cytosolic DNA
also activates IKK and IKK (Fig. 2B) (13) and that the optimal
substrate motif of IKK and IKK shares a partial homology to
that of TBK1 and IKK (30, 31, 34, 35). To further investigate
the role of individual IKKs in promoting STAT3 phosphoryla-
tion upon cytosolic DNA challenge, we used an IKK/IKK-
specific inhibitor compound A (36) and two TBK1/IKK-
specific inhibitors, AZ-5C and AZ-5E (37). The TBK1/IKK
inhibitors blocked the induction of phospho-IRF3 and Ser(P)754-
STAT3, whereas phospho-p65 wasmostly unaffected (Fig. 3D).
Tyr705 phosphorylation of STAT3was also dependent onTBK1
and/or IKK (Fig. 3D). In contrast, the IKK/IKK inhibitor
potently blocked the induction of phospho-p65 but had mini-
mal effect on phospho-IRF3, Ser(P)754-STAT3, or Tyr(P)705-
STAT3 in THP-1 cells (Fig. 3D). This indicates that phos-
phorylation of STAT3 Ser754 is mediated by TBK1 and is
independent of IKK and IKK, whereas activation of NF-B
p65 is mediated by IKK and/or IKK. Taken together, our
data demonstrate that TBK1, rather than IKK, IKK, or IKK,
is the principle kinase that mediates Ser754 phosphorylation of
STAT3 upon cytosolic DNA challenge.
The cGAS-STING-TBK1 Pathway Induces STAT3 Ser754
Phosphorylation in Response to Cytosolic DNA—Because the
endoplasmic reticulummembrane protein STING is indispens-
able for cytosolic DNA-induced TBK1 activation (10, 38),
we tested whether STING is also required for STAT3 Ser754
phosphorylation in response to cytosolic DNA. Indeed, knock-
down of STING significantly reduced cytosolic DNA-induced
Ser(P)754-STAT3 (Fig. 4A). Moreover, Ser(P)754-STAT3 can be
induced by ectopic expression of STING in HEK293T cells in a
dose-dependent manner, suggesting that Ser754 phosphoryla-
tion occurs downstream of STING activation (Fig. 4B).We also
tested whether the cytosolic dsDNA sensor cGAS is required in
this setting. Knockdown of cGAS led to reduced activation
of TBK1 and phosphorylation of IRF3 and a moderate reduc-
FIGURE 1. IKK and TBK1 induce STAT3 phosphorylation at Ser754. A, a schematic figure showing the domain structure of STAT3 and the location of Ser754.
Sequences of STAT3 from several vertebrates were aligned to compare the homology, with residues critical for TBK/IKK substrate recognitionmarked in blue
and Ser754 marked in red. Also shown are the domain structure of STAT1 and STAT6, with previously identified IKK/TBK1 target serine residues marked in red
and the sequence alignments shownon the right.NTD, N-terminal domain.B, FLAG-taggedSTAT3 (3g)was co-transfectedwithGST-IKK (3g) intoHEK293T
cells. STAT3 was immunoprecipitated (IP) and blotted with an IKK substrate motif antibody. C, FLAG-tagged wild-type, Y705F, S727A, or S754A STAT3 (3 g)
were co-transfected with wild-type or K38A (kinase-dead; KD) GST-TBK1 (3 g) into HEK293T cells. STAT3 was immunoprecipitated and blotted with phos-
phorylation-specific antibodies to detect Ser754, Tyr705, and Ser727 phosphorylation. D, in vitro kinase assay using the GST-tagged C terminus of STAT3 and
GST-TBK1 purified from HEK293T as described under “Experimental Procedures.” The mixture was resolved by SDS-PAGE and blotted (WB) with GST and
Ser(P)754-STAT3 antibodies. Phosphorylation of STAT3 was also detected by autoradiography. Data in B–D are representative of four, three, and two indepen-
dent experiments, respectively.
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tion in the levels of Ser(P)754-STAT3 (Fig. 4C). The moderate
reduction of Ser(P)754-STAT3 may be due to incomplete
knockdown of cGAS or the redundancy of other cytosolic DNA
sensors. Activation of cGAS by cytosolic DNA leads to produc-
tion of cGAMP, which subsequently promotes STING activa-
tion and activation of the TBK1-IRF3 signaling axis. We found
that transfection of cGAMP is sufficient to induce Ser754 phos-
phorylation of STAT3 (Fig. 4D), further supporting the model
in which Ser754 phosphorylation of STAT3 occurs downstream
of STING. These data demonstrate that cytosolic DNA engages
cGAS and STING to activate TBK1 and induce STAT3 Ser754
phosphorylation.
SecretedCytokines InduceActivation of STAT3 in Response to
Cytosolic DNA—We next set out to determine the mechanism
of STAT3 activation (as marked by Tyr705 phosphorylation) in
response to cytosolicDNA. InTHP-1 cells, activation of STAT3
was suppressed by TBK1/IKK inhibitors (Fig. 3D), suggesting
that TBK1 kinase activity is required for STAT3 activation.
Because TBK1 is not a tyrosine kinase, activation of STAT3 is
probably mediated by tyrosine kinases that are directly or indi-
rectly activated by TBK1. It is well established that Janus
kinases (JAKs) activate STAT3 by phosphorylating Tyr705. We
thus asked whether JAKs are involved in STAT3 activation in
response to cytosolic DNA. Treating the cells with a pan-JAK
inhibitor, pyridine 6 (39), effectively blocked STAT3 phosphor-
ylation at Tyr705, but TBK1 activation and phosphorylation of
STAT3 at Ser754 was unaffected (Fig. 5A). These data and the
TBK1 inhibitor data (Fig. 3D) suggest that cytosolic DNA-in-
duced STAT3 activation is primarily mediated by JAKs, the
activation of which is dependent on TBK1. Because JAKs usu-
ally function downstream of cytokine receptors, we hypothe-
sized that cytosolicDNA induces production of cytokines, lead-
ing to activation of the JAKs and STAT3 through an autocrine
mechanism. An alternative hypothesis would be that TBK1
activates JAKs directly or through a cascade of kinase activation
in a cell-autonomous manner. To test these hypotheses, we
asked whether conditioned media from dsDNA-transfected
cells are able to activate STAT3 in naive recipient cells. We
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FIGURE2.CytosolicDNA induces STAT3activationandphosphorylationat Ser754.A, L929 cellswere transfectedwith poly(I:C), poly(dA:dT), or VACV70mer
(hereafter referred to as dsDNA) using Lipofectamine 2000; treated with 1 g/ml LPS; or serum-starved for 3 h. Lysates were analyzed by Western blotting to
determine the levels of TBK1, IRF3, and STAT3 activation. B, THP-1 cells were treated as described in A or treated with 1 g/ml flagellin for 3 h. Lysates were
analyzed by Western blotting, and STAT3 was immunoprecipitated (IP) and blotted for co-precipitated IKK or TBK1. C, a time course analysis of signaling
responses to cytosolic DNA. THP-1 cells weremock-transfected or transfectedwith dsDNAand analyzed byWestern blotting at the indicated times. STAT3was
immunoprecipitated and blotted for Ser(P)754 and co-precipitated TBK1. Data in this figure are representative of two independent experiments.
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found that conditionedmedia from dsDNA-transfected THP-1
strongly inducedTyr(P)705-STAT3 but not Ser(P)754-STAT3 in
the recipient cells (Fig. 5B, lanes 10–14). When cells were
treated with cycloheximide immediately before dsDNA trans-
fection to block protein synthesis, the ability of conditioned
media to induce Tyr(P)705-STAT3 in the recipient cells was
abrogated (Fig. 5B, lanes 15–18). Although the possibility of
cell-autonomous TBK1-mediated JAK activation cannot be
completely ruled out because a weak STAT3 activationwas still
observed in cycloheximide-treated cells (Fig. 5B, lanes 6–9),
these results argue that STAT3 activation is primarily medi-
ated by de novo synthesized secreted factors. We noticed
that expression of several STAT3-activating cytokines, includ-
ing IL-6 and IFN, was induced by cytosolic DNA, and the
induction of IFNwas blunted by TBK1 inhibitor (supplemen-
tal Fig. 1). Therefore, we tested the involvement of IL-6 and
IFN in STAT3 activation. Indeed, an IFN-neutralizing
antibody reduced the ability of conditioned media to activate
STAT3 in the recipient cells, and an IL-6-neutralizing antibody
also had a modest effect (Fig. 5C). Taken together, our data
show that cytosolic DNA-induced Ser754 phosphorylation of
STAT3 is strictly cell-autonomous, whereas Tyr705 phosphor-
ylation, and thus activation of STAT3, is primarily mediated
by secreted factors, such as IFN, through an autocrine
mechanism.
Ser754 Phosphorylation of STAT3 Restricts Cytosolic DNA-
induced STAT3 Target Gene Expression—Next, we sought to
determine the effect of cytosolic DNA-induced Ser754 phos-
phorylation on STAT3 activation and target gene expression.
THP-1 cells reconstituted with wild-type or mutant STAT3
following CRISPR-mediated knock-out (supplemental Fig. 2)
were transfected with dsDNA to induce STAT3 activation and
Ser754 phosphorylation. Activation of wild-type and S754D
STAT3 by cytosolic DNA was significantly lower than that of
the S754A mutant, suggesting that Ser754 phosphorylation
inhibits STAT3 activation (Fig. 6A). STAT1 and p65 were also
activated by cytosolic DNA, but their activation was not
affected by the status of STAT3, and p65 showed constitutive
association with STAT3 (Fig. 6A). We also examined the gene
expression induced by cytosolic DNA. STAT3 target gene
SOCS3 was up-regulated in the presence of STAT3 (Fig. 6B),
and its expression was further elevated in the S754A cells, con-
sistent with increased activation of the S754Amutant (Fig. 6A).
The NF-B target gene IL6 was also up-regulated in the pres-
ence of STAT3, but Ser754 phosphorylation did not have any
measurable effect on its expression (Fig. 6C). This suggests that
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there may be cooperative binding and transcriptional activa-
tion between STAT3 and NF-B in regulating IL-6 transcrip-
tion, but Ser754 phosphorylation of STAT3 does not affect the
gene expression mediated by this complex. In agreement with
this hypothesis, the interaction between p65 and STAT3 was
not affected by cytosolic DNA or the status of Ser754 phosphor-
ylation (Fig. 6A). We also asked whether Ser754 phosphoryla-
tion of STAT3 modulates the inhibitory effect of STAT3 on
ISGF3 target genes (25) and found that CXCL10 was down-
regulated bywild-type andmutant STAT3 to similar levels (Fig.
6D), suggesting that Ser754 phosphorylation is not involved in
the inhibition of ISGF3 target genes by STAT3. Finally, chro-
matin immunoprecipitation demonstrated that upon cytosolic
DNA challenge, STAT3 was recruited to the predicted binding
sites in SOCS3 promoter (Fig. 6E) and that the increased abun-
dance of S754A STAT3 at the SOCS3 promoter correlated with
gene expression levels (Fig. 6B). These data demonstrate that
cytosolic DNA-induced Ser754 phosphorylation of STAT3
dampens the expression of STAT3 target gene without affect-
ing the expression of NF-B or ISGF3 genes.
Ser754 Phosphorylation Suppresses the Transcriptional Activ-
ity of STAT3—Because Ser754 is located in the transactivation
domain of STAT3, we hypothesized that phosphorylation at
Ser754 modulates the transcriptional activity of STAT3 in
response to IL-6 and IFN.We askedwhether Ser754 phosphor-
ylation of STAT3 affects the expression of a STAT reporter
containing tandem GAS sites in response to IFN and IL-6 by
using a phosphomimeticmutant (S754D), because Ser754 phos-
phorylation is not induced by IFN or IL-6 alone. To avoid
interference from endogenous STAT3, the reporter assay
was carried out using CRISPR-mediated STAT3 knock-out
HEK293T cells (supplemental Fig. 2) or STAT3-null MEFs sta-
bly expressing wild-type or mutant STAT3. We found that
IFN induced a much higher expression of the STAT report-
er in the presence of wild-type STAT3, but the transcriptional
inactive Y705F mutant inhibited reporter expression (Fig. 7A),
indicating that STAT3 contributes to GAS-driven gene expres-
sion in response to IFN. The reporter expression was reduced
with the S754Dmutant, suggesting an inhibitory role for Ser754
phosphorylation in the transcriptional activity of STAT3 (Fig.
7A). In contrast, STAT3did not affectGAS-driven gene expres-
sion in response to IFN (Fig. 7A), which predominantly acti-
vates STAT1 but not STAT3 (15). The S754D mutant also
showed decreased activation upon IFN stimulation (Fig. 7B),
consistent with the results from reporter assays.We then asked
whether TBK1-induced Ser754 phosphorylation affects STAT3
activation in response to IFN. Because overexpression of
TBK1 leads to significant production of cytokines, resulting
in elevated basal STAT3 activation (40) (Fig. 1C), here we
expressed amoderate amount of TBK1 before treating the cells
with IFN. We found that TBK1 expression suppressed IFN-
induced STAT3 activation, but the S754A mutant was more
refractory to this TBK1-mediated inhibition (Fig. 7C, lanes 5
and 7). These data show that Ser754 phosphorylation inhibits
IFN-induced activation of STAT3. We also probed the possi-
bility that Ser754 phosphorylation of STAT3may affect STAT3-
mediated inhibition on ISGF3 target genes. Consistent with
CXCL10 expression in THP-1 cells (Fig. 6D), wild-type and
mutant STAT3 inhibited IFN-induced ISRE reporter expres-
sion to comparable levels (supplemental Fig. 3), indicating that
Ser754 phosphorylation of STAT3 does not affect ISGF3 activ-
ity. Similar to the IFN reporter assays, S754Dmutant was also
less active in response to IL-6 as measured by STAT reporter
assays and by the levels of Tyr705 phosphorylation, which
pS754-STAT3
STAT3
GST
Flag
2 1.6 1.2 0.2 1.8-
- 0.4 0.8 1.8 --
- - - - 0.2-GST-TBK1 (μg)
Flag-STING (μg)
pcDNA3 (μg)
p-TBK1
pS754-STAT3
p-IRF3
p-p65
TBK1
STAT3
IRF3
STING
cGAMP    -     m  1.5h 3h
p-TBK1
TBK1
pS754-STAT3
STAT3
p-IRF3
IRF3
siCTRL sicGAS
dsDNA (3h) m   + m   +
siCtrl sicGAS
0.0
0.5
1.0
1.5
R
el
at
iv
e 
qu
an
tit
y
cGAS expression
pS754-STAT3
STAT3
p-TBK1
TBK1
p-IRF3
IRF3
STING
dsDNA (hr) m   1    2    3 m   1   2    3
siCtrl siSTING
A B
C D
80
80
80
80
50
50
40
kDa
80
80
110
40
kDa
80
50
60
80
80
50
40
kDa
80
80
80
80
50
50
kDa
80
FIGURE 4. Cytosolic DNA induces Ser(P)754-STAT3 via the cGAS/STING axis. A, L929 cells were transfected with control or IKK siRNA. Forty-eight hours
post-transfection, cellswere transfectedwithdsDNAandanalyzedbyWesternblotting at the indicated timepoints.B, increasing amounts of STINGexpression
plasmid were transfected into HEK293T cells with decreasing amounts of pcDNA3 empty vector, such that the same amount of total DNA was used in every
transfection. After 24 h, cells were lysed and blotted for Ser(P)754-STAT3. GST-TBK1-transfected cells were used as a positive control. C, L929 cells were
transfected with control or cGAS siRNA. After 68 h, cells were harvested for qRT-PCR tomeasure cGAS expression levels or transfected with dsDNA for 3 h and
analyzed byWestern blotting. The expression of cGAS was normalized to Gusb. D, L929 cells were mock-transfected or transfected with cGAMP and analyzed
by Western blotting. Data in A and B–D are representative of three and two independent experiments, respectively. Error bars, S.D.
TBK1 Regulates STAT3 Activity in Response to Cytosolic DNA
5410 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 13•MARCH 31, 2017
inversely correlatedwith the levels of Ser754 phosphorylation or
phosphomimetic mutation (Fig. 7,D and E). Collectively, these
data demonstrate that Ser754 phosphorylation suppresses the
transcriptional activity of STAT3 induced by IL-6 and IFN.
Discussion
In this study, we identified STAT3 as a novel substrate of
TBK1 downstream of the cytosolic DNA pathway. In the pres-
ence of cytosolic DNA, TBK1 phosphorylates STAT3 at Ser754
to limit STAT3 activity induced by cytokines, such as IL-6 and
IFN. Previously, it has been shown that IKK regulates STAT1
dimerization and that TBK1 regulates STAT6 activity by direct
phosphorylation (14, 26). Our finding places a third STAT
member under the control of IKK/TBK1. Interestingly,
the IKK/TBK1-mediated phosphorylation sites in STAT1,
STAT3, and STAT6 differ in their location within the proteins
(Fig. 1A). In the case of STAT1, phosphorylation of Ser708,
which resides between the SH2 domain and the TAD, disrupts
SH2 domain-mediated STAT1 homodimerization by steric
hindrance (26). How TBK1-mediated Ser407 phosphorylation
regulates the activity of STAT6 is less clear. Ser407 resides
within a highly conserved region of the STAT DNA binding
domain, and structural analysis demonstrated that mutations
in this region abolish the DNA binding ability of STATs (41).
Thus, it is plausible that Ser407 phosphorylation affects the
DNA binding affinity of STAT6. It is also worth noting that
TBK1 induces a reduced but still significant phosphorylation
on STAT6 S407Amutant (14), suggesting the existence of addi-
tional TBK1 phosphorylation sites in STAT6. In fact, we iden-
tified another IKK/TBK1 substrate motif in STAT6 TAD,
in which Ser733 is the residue that corresponds to Ser754 of
STAT3. Our preliminary data suggest that TBK1 overexpres-
sion also leads to STAT6 phosphorylation at Ser733.4 For future
investigations, it would be of interest to determine whether this
phosphorylation serves as an additional mechanism by which
TBK1 regulates STAT6 activity in a manner similar to what we
discovered with STAT3.
The two IKK-related kinases TBK1 and IKK are structurally
similar and prefer almost identical substrate sequences in vitro
(30, 31). However, they appear to have distinct yet partially
overlapping roles in vivo (42). Studies using TBK1 or IKK
knock-out cells showed that TBK1 is the principle kinase that
phosphorylates IRF3 to initiate interferon production in
response to innate immune stimuli and pathogens, whereas
IKK has aminor or negligible role in activating IRF3 and inter-
feron production (11, 43, 44). Similarly, in our model, although
overexpression of TBK1 and IKK both induced Ser754 phos-
phorylation of STAT3 (Fig. 1, B and C), endogenous IKK did
not have a measurable impact on STAT3 phosphorylation in
response toVACV70mer (dsDNAwith 33%GC content) trans-
fection (Fig. 3C). However, it is worth noting that whereas
VACV70mer only induced interaction between STAT3 and
TBK1, poly(dA:dT) transfection induced interaction of STAT3
with TBK1 and IKK (Fig. 2B), suggesting that IKK may con-
tribute to the signaling cascades and STAT3 phosphorylation
downstream of AT-rich cytosolic DNA. AT-rich cytosolic
DNA not only activates the STING-TBK1 pathway but also
engages the cytosolic dsRNA sensor RIG-I by a polymerase III-
dependent mechanism (45). Thus, the differential interactions
between STAT3 and IKK/TBK1 in response to VACV70mer
and poly(dA:dT) may be due to the activation of cytosolic
dsRNA pathway specifically downstream of poly(dA:dT). It is
also conceivable that IKK will play a more dominant role in
scenarios where its expression is highly induced (46). Whether
IKK contributes to STAT3 Ser754 phosphorylation and regu-
lation under these conditions remains to be tested.
The NF-B pathway is also activated by cytosolic DNA, but
the roles of different IKKs in this context remain controversial
(11–13). Ishii et al. (11) suggested that TBK1 is dispensable for
4 H.-C. Hsia, unpublished observation.
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cytosolic DNA-induced NF-B activation, whereas Abe et al.
(12, 13) demonstrated a significant dependence of NF-B acti-
vation on TBK1. In MEFs and THP-1 cells, we observed that
IKK/IKK and TBK1 are each responsible for cytosolic DNA-
induced p65 NF-B activation or IRF3 activation (Fig. 3, A and
D), indicating that the signaling events dictating NF-B and
IRF3 activation diverge at or above the level of these kinases.
Intriguingly, p65 activation in L929 is mostly dependent on
TBK1 (Fig. 3B), consistent with the observationmade by Abe et
al. (13). It is unclear why such differences exist. One possible
explanation may be the availability of different signaling mole-
cules and the formation of different complexes. For instance,
depending on the cell type, TBK1may localize to themitochon-
dria or the endoplasmic reticulum in response to cytosolic
DNA (47). Therefore, it is likely that signaling pathways down-
stream of cytosolic DNA and STING may be influenced by the
availability of cell type-specificmachinery and platforms aswell
as the subcellular localization of TBK1.
Although it is unclear why Ser754 phosphorylation dampens
the activity of STAT3, studies on a natural occurring STAT3
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isoform STAT3 provide a plausible hypothesis. Alternative
splicing of the STAT3 transcript results in the truncated
STAT3 isoform that is 48 amino acids shorter than the full-
length STAT3 (48). STAT3 shows strong Tyr705 phosphor-
ylation and DNA binding activity even in the absence of stim-
ulation, but it lacks intrinsic transcriptional activity due to the
lack of TAD (48, 49). Interestingly, STAT3 dimers are more
stable than dimers formed by full-length STAT3, and deletion
of 19 residues at the C terminus (amino acids 752–770) of full-
length STAT3 is sufficient to significantly enhanceTyr705 phos-
phorylation, DNA binding activity, and dimer stability (50).
Because the C terminus of STAT3 is rich in acidic amino acids
that are negatively charged, it was therefore proposed that the
cluster of negative charges in the TAD interferes with STAT3
dimerization and makes phosphorylated Tyr705 more accessi-
ble to phosphatases (50). Given this mechanism, phosphoryla-
tion or phosphomimeticmutation of Ser754will introducemore
negative charges to the region and may destabilize STAT3
dimers, thereby reducing its transcriptional activity. Alterna-
tively, it is also possible that Ser754 phosphorylation affects the
interaction between STAT3 and its co-activators to modulate
STAT3 activity. Future studies will focus on testing these
hypotheses.
There is mounting evidence of the critical role of cytosolic
DNA in tumorigenesis and anti-tumor immune responses.
Functional loss of the cGAS-STING cytosolic DNA pathway
has been observed in some commonly used cell lines and high
passage immortalizedMEFs (5) as well as colorectal cancer and
melanoma, in which loss of the cytosolic DNA pathway corre-
lates with tumor progression (27, 28). In a mouse model of
colitis-associated colorectal cancer, STING-deficient mice
showed elevated NF-B and STAT3 activity and developed
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advanced disease, suggesting a role of STING in controlling
inflammatory responses and tumorigenesis (29). According to
our model, loss of the cytosolic DNA sensing pathway will pre-
dict loss of the TBK1-mediated restraint on STAT3 activity,
allowing the tumor cells to have elevated STAT3 activation in
response to cytokines such as IL-6. Given the well established
role of STAT3 in promoting tumorigenesis, our finding sug-
gests a possible mechanism in which tumor cells without the
cytosolic DNA pathway may have a survival advantage due to
unchecked STAT3 activation. On the other hand, activation of
dendritic cells in the tumormicroenvironment by engaging the
cGAS/STING pathway leads to significant T cell recruitment
and anti-tumor immunity (51, 52). Because STAT3 negatively
regulates dendritic cell activity and the anti-tumor response of
hematopoietic cells (20, 53), cytosolic DNA-mediated restraint
on STAT3 activity may serve as an additional mechanism to
strengthen the anti-tumor immunity of hematopoietic cells in
the tumor microenvironment.
In summary, we identified a novel signaling axis in which
TBK1modulates STAT3 activity in response to cytosolic DNA.
Our findings reveal a new mechanism by which the activity
of STAT3 can be fine-tuned by a single phosphorylation and
shed light on the possible cross-talk between innate immune
responses and STAT3-driven oncogenic pathways.
Experimental Procedures
Plasmids and Viruses—Mouse STAT3 was cloned into
pBabe-puro (Addgene, catalog no. 1764) (54) using BamHI and
EcoRI. N-terminal HA-tagged STAT3 was cloned into 3XHA-
pEBB vector using BamHI and NotI. N-terminal FLAG-tagged
STAT3 was cloned into pENTR-3C plasmid using BamHI
and EcoRI, followed by Gateway recombination into pLenti6/
UbC/V5 destination vector (Thermo Fisher). The C terminus
of STAT3 (amino acids 700–770) was cloned into pGEX-4T-1
in framewithN-terminal GSTusing BamHI and EcoRI. STAT3
mutant plasmids were generated by site-directed mutagenesis
andconfirmedbysequencing.STAT3CRISPRplasmidwascon-
structed using lentiCRISPRv2 (Addgene, catalog no. 52961)
(55) with a single guide RNA targeting the 5-UTR of human
STAT3 (supplemental Fig. 2). The primer sequences for single
guide RNA cloning are as follows: 5-CAC CGT GCC GGA
GAA ACA GGT GAA G-3 and 5-AAA CCT TCA CCT GTT
TCT CCG GCA C-3.
Protein Purification and in Vitro Kinase Assay—Rosetta cells
(Novagen) harboring pGEX-4T-1-STAT3 plasmid were grown
to log phase and treated with 0.5 mM isopropyl -D-1-thioga-
lactopyranoside at 30 °C for 16 h. The cells were lysed (50 mM
Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, 25 g/ml
lysozyme, protease inhibitor mixture (Promega)) at room tem-
perature, followed by the addition of 1.25g/ml sodiumdeoxy-
cholate, 1.25 M MgCl2, and 62.5 g/ml DNase I. Cleared
lysates (13,000 rpm, 15min, 4 °C) were incubatedwith glutathi-
one-agarose beads (Amersham Biosciences) at 4 °C for 2 h. The
beads were washed twice with modified RIPA buffer (150 mM
NaCl, 1% Nonidet P-40, 0.25% sodium deoxycholate, 50 mM
Tris, pH 7.6, 1 mM -glycerol phosphate), twice with high salt
(500 mM NaCl) modified RIPA, and twice with kinase buffer (1
mM -glycerol phosphate, 20 mM Tris, pH 7.4, 12 mM MgCl2).
Purified protein was eluted by incubating the beads with 30mM
glutathione in kinase buffer with 0.1% Tween 20 for 20 min at
room temperature with shaking.
Wild-type and K38A GST-TBK1 were purified from
HEK293T transfected with pEBG-GST-TBK1 plasmids as
described previously (31). For in vitro kinase assays, 1–2 l of
purified GST-STAT3 was incubated with 2–4 l of wild-type
GST-TBK1 or K38A GST-TBK1 in kinase buffer with 1 mM
ATP and 10 Ci of [-32P]ATP at room temperature for 2 h.
The reaction was resolved by SDS-PAGE, followed by immu-
noblotting or autoradiography.
Cells—THP-1 cells were maintained in RPMI1640 with 10%
FBS, whereas HEK293T, L929, and MEFs were maintained in
DMEM with 10% FBS and kept at 37 °C with 5% CO2. STAT3-
null MEFs were a gift from Dr. Hua Yu (City of Hope), and
TBK1 null MEFs were a gift from Amgen. Retroviruses were
produced by co-transfection of pBabe-puro-STAT3 and
pCL10A1 plasmids into HEK293T cells, and lentiviruses were
produced by co-transfection of pLenti6-STAT3 with psPAX2
and pMD2.G intoHEK293T cells. The supernatants containing
viruses were 0.45 m-filtered before being used for transduc-
tion. To reconstitute STAT3 expression in STAT3-null MEFs,
MEFs were transduced with pBabe-puro-STAT3 retroviruses
and selected for puromycin resistance. To generate STAT3
CRISPR knock-out cells, THP-1 or HEK293T cells were trans-
duced with STAT3 CRISPR virus and selected for puromycin
resistance, and single clones were analyzed for STAT3 knock-
out efficiency (supplemental Fig. 2). To reconstitute STAT3 in
THP-1, STAT3-THP-1 cells were transduced with pLenti6-
STAT3 viruses and selected for blasticidin resistance.
To activate TBK1, cells were transfectedwith poly(I:C), poly-
(dA:dT), VACV70mer, or 2-3 cGAMP using Lipofectamine
2000 (Thermo Fisher) at a 1:1 ratio (g/l), and the final con-
centration of nucleic acids was 2g/ml unless otherwise noted.
THP-1 cells were treated with 25 ng/ml phorbol 12-myristate
13-acetate (Sigma, P1585) overnight to induce adherence
before cytosolic DNA transfection. Poly(I:C) (tlrl-pic) poly(dA:
dT) (tlrl-patn), cGAMP (tlrl-cga23), and LPS (tlrl-eblps) were
from Invivogen. VACV70mer was prepared by annealing com-
plementary 70-nucleotide primers as described previously (33).
For experiments with conditioned media, supernatants from
nucleic acid transfected cells were collected and 0.2 m-fil-
tered; mixed with 20 g/ml normal mouse IgG (Millipore,
12-371), 20 g/ml human IL-6-neutralizing antibody (R&D
Systems,MAB206), or 40g/ml human IFNneutralizing anti-
body (BioLegend, catalog no. 514004); and incubated at room
temperature for 20 min before being added to recipient cells.
Transfection of siRNA—Transfection of siRNA was carried
out using Lipofectamine 2000 according to the manufac-
turer’s protocol. Mouse Tbk1 (M-063162-01-0005), mouse
Ikbke (IKK) (M-040798-01-0005), mouse Tmem173 (STING)
(M-055528-01-0005), and control siRNAs (D-001210-03-05)
were from Dharmacon. Mouse Mb21d1 (cGAS) siRNA was
from Sigma (SASI_Mm01_00129826)
Reporter Assay—The STAT reporter 4xM67 pTATA TK-
firefly luciferase plasmid (Addgene, catalog no. 8688) (56) and
pRL-TK-Renilla luciferase plasmid (Promega) were co-trans-
fected at 15:1–20:1 ratios into STAT3 293T cells together
TBK1 Regulates STAT3 Activity in Response to Cytosolic DNA
5414 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 13•MARCH 31, 2017
with 4xHA-STAT3 plasmids. Twenty-four hours after trans-
fection, cells were treated with 25 pg/ml mouse IFN (R&D
Systems, 8499-IF-010) or 200 pg/ml mouse IFN (R&D Sys-
tems, 285-IF-100). Cells were lysed with passive lysis buffer
(Promega) for the Dual-Luciferase assay (Promega) at 16–24 h
after treatment. The relative luciferase units (RLU) were calcu-
lated by normalizing the reading of firefly luciferase to that of
Renilla luciferase, and RLU of the control cells was set to 1. For
IL-6 reporter assays, STAT3 reconstituted MEFs were trans-
fected with reporters in the same manner and treated with 100
ng/ml mouse IL-6 (BioLegend, catalog no. 575704) for 24 h.
Immunoblotting and Immunoprecipitation—For immuno-
blotting, cells were lysed in RIPA buffer with protease inhibitor
mixture (Promega), phosphatase inhibitor mixture (Sigma),
and 1mMNa3VO4. Cleared lysateswere resolved by SDS-PAGE
(NuPAGE bis-tris gels, Thermo Fisher), transferred to PVDF
membranes (Millipore, IPVH00010), and blocked in 5% nonfat
milk in TBST. Themembranes were incubated in primary anti-
bodies (1:1000–1:5000) inTBST at 4 °C overnight, washedwith
TBST, and incubated in appropriate HRP-conjugated second-
ary antibodies (Promega) (1:10,000). Pierce ECL (Thermo
Fisher) was added to the blots, which were then exposed to
films and developed or imaged using ChemiDoc (Bio-Rad). For
immunoprecipitation, cells were lysed in 0.5% Nonidet P-40
buffer (0.5%Nonidet P-40, 150mMNaCl, 20 mMTris, pH 7.6, 1
mM EGTA, 1 mM EDTA, 1 mM -glycerol phosphate, and
0.5% glycerol) with protease and phosphatase inhibitors and
Na3VO4. Cleared lysates were incubated with M2 FLAG
(Sigma) or STAT3 antibodies at 4 °C overnight, followed by
incubation with Dynabead protein G (Thermo Fisher) for 1 h at
4 °C and washing with 0.5% Nonidet P-40 buffer, and resolved
by SDS-PAGE and immunoblotting. The following antibodies
were from Cell Signaling Technology: GST (catalog nos. 2624
and 2625), phospho-IKK/IKK (Ser176/Ser180) (catalog no.
2697), IKK (catalog no. 2684), IKK (catalog no. 3416), phos-
pho-IRF3 (Ser396) (catalog no. 4947), IRF3 (catalog no. 4302),
phospho-TBK1 (Ser172) (catalog no. 5483), TBK1 (catalog no.
3013), phospho-STAT3 (Tyr705) (catalog nos. 9145 and 9132),
phospho-STAT3 (Ser727) (catalog no. 9134), phospho-p65
(Ser536) (catalog no. 3033), p65 (catalog no. 8242), STING (cat-
alog no. 13647), phospho-STAT3 (Ser754) (BL14578; catalog
no. 5163), and IKK phosphosubstrate motif (G9108). The IKK
phosphosubstratemotifantibodywasgeneratedagainstthephos-
phorylated IKK consensus sequenceX(Y/F)XpSLX, where pS is
the phosphoserine targeted by IKKs (30, 31, 34, 35). GAPDH
(sc-25778) and -tubulin (sc-9104) antibodies were from Santa
Cruz Biotechnology, Inc. Densitometry analyses were carried
out using the gel analysis function of ImageJ.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation (ChIP) was performed as described previously (57).
Briefly, cells were fixed by formaldehyde, lysed, and sonicated
to yield DNA fragments of 200–500 bp. Lysates were diluted to
0.1% of SDS and precleared by incubatingwith BSA and salmon
sperm DNA-blocked Dynabead magnetic protein G beads
(Thermo Fisher). Lysates corresponding to 5  106 cells were
used for eachChIPwith 5g of rabbit IgG (Cell SignalingTech-
nology, catalog no. 2729) or rabbit anti-STAT3 antibody (Cell
Signaling Technology, catalog no. 12640), followed by capture
with Dynabead magnetic protein G beads. DNA-protein-anti-
body complexes were eluted, and DNAwas uncross-linked and
purified by phenol-chloroform. The quantity of inputDNAwas
determined byNanodrop. The quantity of DNA corresponding
to the STAT3 binding site in the SOCS3 promoter in immuno-
precipitated chromatin was determined by qRT-PCR with
three technical repeats using SYBRGreen (Thermo Fisher) and
the following primers: 5-TAA GAA GGC TGA TTT CTG
GCAGAGG-3 and 5-CCAGGTCGGCCTCCTAGAACT-
3. Data are shown as mean with S.D. and are representative of
two independent experiments.
Quantitative Real-time PCR—Total RNA from cells were
purified using the Qiagen RNeasy Plus kit according to the
manufacturer’s protocol. 1–2g of RNAwas used to synthesize
cDNAusingMoloneymurine leukemia virus reverse transcrip-
tase (Thermo Fisher). Quantitative real-time PCR (qRT-PCR)
was carried out using synthesized cDNA and standard TaqMan
probes, primers, and reagents (Thermo Fisher). The expression
level of target geneswas calculated by theCtmethod relative
to the level ofGUSB. Data shown are the relative quantity, with
the relative quantity of the control cells set to 1.
Statistical Analysis—For reporter assays and qRT-PCR, data
are shown as mean with S.D. or mean with 95% confidence
intervals, respectively. Each data point was from three technical
replicates. Analyses were done by Prism (GraphPad Software,
Inc., La Jolla, CA) using a t test with false discovery rate con-
trolled at 1%.
Inhibitors and Reagents—The IKK/IKK-specific inhibitor
Compound A was a generous gift from Dr. Karl Ziegelbauer
(Bayer). The TBK1/IKK-specific inhibitors AZ-5C and AZ-5E
were synthesized by Dr. Stephen Frye’s group at the University
of North Carolina (Chapel Hill, NC). The pan-JAK inhibitor
pyridone 6 was fromMillipore (catalog no. 420099), and cyclo-
heximide was from Sigma (C7698).
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